Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lilly Executes Growth Strategy As New Products Drive Sales Gains

Executive Summary

Eli Lilly & Co.'s first quarter earnings met analyst expectations with help from recently approved products, but greater growth in future years depends on a closely-watched Phase III Alzheimer's program.


Related Content

1Q Earnings Preview: What To Expect From US, EU Big Hitters
FDA OK's Lilly's Taltz; Rival To Novartis' Cosentyx
PIPELINE WATCH – 10 Approvals, Two Breakthroughs And A Refusal To File Letter
Diabetes Manufacturers Brace Under Shifting Market Dynamics
Lilly Loses UK High Court Alimta Battle
Lantus Follow-On Basaglar OK'd, But Can Lilly Sell It?
Lilly's Lung Cancer Drug Portrazza OK'd
Who Suffers From Lilly's Evacetrapib Failure?
FDA OK's Lilly's Cyramza in colon cancer
Lilly vows appeal of Alimta patent ruling in Germany


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts